Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

Open-Label,Multicenter Study of G17DT Immunogen in Combination w/ Cisplatin and 5-FU in Subjects w/ Metastatic or Locally Recurrent Gastric or Gastroesophageal Cancer Previously Untreated With Chemotherapy.

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.

Inclusion criteria:

• Clinical diagnosis with gastric or gastroesophageal cancer
• Karnofsky performance status score of at least 70
• Life expectancy of at least 3 months

Exclusion criteria:

• Prior treatment with chemotherapy or anticancer immunotherapy
• Bone marrow transplant within past year
• Chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease
• Central nervous system metastases
• Immunodeficiency
• Hypercalcemia